Home > Products > Albumin Removal Kits >

AlbuSorb™ - Albumin Depletion Kit



 
Alternative Views:


Functional Proteomics
Price: $325.00


Product Code: A185


Size (A185):
  

Qty:
Description Applications Specifications
 
  • Removes >90% albumin from 30 mg albumin/ml sample
  • Affinity-type equivalence, virtually no cross-reactivity with other proteins
  • Bind and elute procedure - simply weigh powder, condition the sample, centrifuge and/or filter, and recover the albumin depleted serum
  • Economical surface technology, not based on blue-dye or immuno-affinity chromatography
  • Mild conditions maintain tertiary structure of proteins and simple transfer to secondary analysis
  • The albumin depleted filtrate retains the enzymatic and biological activity
  • Removes albumin from samples such as serum, plasma and from most species including human, mouse, sheep, bovine, goat, rat, and calf
  • The flow through fraction is compatible with LC-MS, activity based protein profiling and proteomic studies.

AlbuSorb™ is an albumin depletion reagent supplied as a kit with necessary buffers. With 25ul of starting sample, the yield of albumin depleted serum protein is 0.1-0.2 milligrams. AlbuSorb™ binds albumin from serum or plasma and is compatible with downstream proteomics methods such as protein array pixelation ,1D and 2D gel electrophoresis, LC/MS, and MALDI-TOF MS. Samples are also prepared for biomarker discovery, toxicological studies for new drugs, enzyme assays, protein profiling using SELDI analysis and cytokines research.

AlbuSorb™ binds to albumin, and serum proteins flow through. Removal of albumin allows enhanced detection of low abundance proteins. AlbuSorb™ comes from a silica-based, separation platform utilizing a new combination of surface microenvironments substituted with low molecular substrates that feature drug-binding motifs. Unlike immuno-affinity, the surfaces utilized are disposable eliminating cycle to cycle variance and cross-contamination.

Biotech Support Group has AlbuVoid™ for albumin depletion plus low abundance serum protein enrichment. Both AlbuSorb and AlbuVoid™ are available in AlbuTrial™ kit™. AlbuTrial™ kit™ includes 1 gm of AlbuSorb and 5 Preps of AlbuVoid™ with respective buffers.



Click here to view AlbuSorb™ Product Sheet
References

Serum or plasma
Åvall, Karin. "In vivo and in vitro studies of apolipoprotein CIII in diabetes." (2017).

Cerebrospinal Fluid
Gwenael Pottiez, Pawel Ciborowski. Proteomic Profiling of Cerebrospinal Fluid Expression Profiling In Neuroscience Neuromethods.2012;64:245-270

Synovial fluid
Happonen KE, Fürst CM, Saxne T et al. PRELP protein inhibits the formation of the complement membrane attack complex.Journal of Biological Chemistry.2012;287(11):8092-100

Serum
Berggren, Per-olof, and Lisa Juntti-berggren. "Methods for treating and/or limiting development of diabetes." U.S. Patent No. 20,170,037,118. 9 Feb. 2017.

Swapan Roy, Matthew Kuruc. The Functional Subproteomes of Serpin Protease Inhibitors are Now Open for LC-MS Biomarker Discovery. MOJ Proteomics Bioinform 2016, 3(6): 00106

Dr.Swapan Roy; Amenah Soherwardy; Ravish Amin; Matthew Kuruc Biotech Support Group LLC, Monmouth Junction, NJ - Application Report. AlbuSorb™ Product Extension combines Albumin and Immunoglobulin Depletion in a Consumable Format

Holmberg R, Refai E, Höög A.Lowering apolipoprotein CIII delays onset of type 1 diabetes. Proceedings of the National Academy of Sciences.2011;108(26):10685-9.

Tang MX, Ogawa K, Asamoto M. Effects of Nobiletin on PhIP-Induced Prostate and Colon Carcinogenesis in F344 Rats Nutrition and Cancer.2011;63(2):227-33

Holmberg, Rebecka Apolipoprotein CIII and Ljungan virus in diabetes 2010. Doctoral Thesis

Lu Q, Zheng X, McIntosh T Development of different analysis platforms with LC-MS for pharmacokinetic studies of protein drugs. Analytical Chemistry.2009;81(21):8715-23

Urine
Zubiri, Irene, et al. "Diabetic nephropathy induces changes in the proteome of human urinary exosomes as revealed by label-free comparative analysis." Journal of proteomics 96 (2014): 92-102.

Patent
Berggren, Per Olaf, Yang, Shao-Nian. 2012. Methods For Treating And/Or Limiting Development Of Diabetes.U.S. Patent 20120328630 Kind Code: A1, filed June 25, 2012, and issued December 27, 2012.